Translational research is at the forefront of psychiatric research. Translational research in psychiatry directly involves the concept of personalized medicine, which aims to identify the more accurate individual treatment, based on clinical, genomic, and environmental information. Creative Biolabs has organized a staff of outstanding scientists who have engaged in the research of translational endpoints for psychiatric disorders for many years. To assist our clients' specific objectives in target validation and qualification for psychiatric disorders, Creative Biolabs is proud to offer the most comprehensive services.
Translational Research for Psychiatric Disorders
The term translational can be characterized as the process of obtaining benefit by converting scientific discoveries from preclinical research into clinical applications, to improve health parameters, consequently decrease morbidity and mortality. Translational research refers to those activities conducted to bridge the gap between drug discovery in preclinical models and drug development in humans. Translational research in psychiatry involves the development of useful animal models of psychiatric disorders and preclinical studies using brain cells. These first steps focus on the evaluation of predictive validity. When validated, phase I translational studies (pharmacokinetics, dose and tolerability) and clinical trial phase II studies (proof of concept trial evaluating efficacy) will be conducted. The next step involves the approval in phase III and the posterior application of new public health policies.
Fig.1 Interface between basic and clinical research in mood disorders translational research. (Machado-Vieira, 2012)
Pharmacokinetic/Pharmacodynamic (PK/PD) in Translational Drug Research
Lack of predictability of clinical efficacy and safety is an important problem facing pharmaceutical research today. Translational PK/PD can integrate data generated from diverse test platforms during discovery and development in a mechanistic framework. The use of PK/PD modeling in translational drug research is a promising approach that provides a better understanding of drug efficacy and safety. It is applied to predict efficacy and safety in humans using in vitro bioassay and in vivo animal data. Therefore, successful implementation of PK/PD modeling in the development cycle could have a substantial impact on the overall efficiency and success of pharmaceutical research. In recent years, PK/PD modeling has become a key success factor in modern drug discovery and development. Currently, it provides the basis for optimization of the dosing regimen and the controlled delivery of new drugs in phase 2 clinical trials. Besides, it is increasingly used for the optimization of the design of phase 3 clinical trials by clinical trial simulation.
Translational Research for Psychiatric Disorders at Creative Biolabs
Our professional technical scientists, comprehensive powerful platform, and abundant experience make Creative Biolabs a perfect partner to help our clients in translational research for psychiatric disorders. Our experienced scientists are acutely aware of the need to translate endpoints between animals and humans. Within the area of translational PK/PD, we address the conversion of the data of combined measures (PK/PD) from the preclinical to the clinical setting. This is strongly needed for optimizing drug discovery processes and promoting the efficient treatment of psychiatric disease. Most recently, PK/PD modeling has also been applied in translational drug research, particularly in interfacing drug discovery and early drug development. We offer high-quality PK/PD modeling service for drug candidate selection, lead optimization and the optimization of early proof-of-concept trials using information from preclinical studies. All our services are customized. For more detailed information, please feel free to contact us or directly send us an inquiry.
References
-
Machado-Vieira, R. Tracking the impact of translational research in psychiatry: state of the art and perspectives. Journal of translational medicine. 2012, 10(1):175. Distributed under Open Access license CC BY 2.0, without modification.
For Research Use Only.
